Boostrix™: a reduced-dose acellular pertussis vaccine for use in adolescents and adults

References

• Wolf J, Daley AJ. Microbiological aspects of bacterial lower respiratory tract illness in children: atypical pathogens. Paediatr. Respir. Rev.8, 212–219 (2007).
   Google Scholar
• Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev.18, 326–382 (2005).
   PubMed Web of Science ®Google Scholar
• Hewlett EL. Bordetella species. In: Principles and Practices of Infectious Diseases (Volume 2). Mandell GL Bennett JE, Dolin R (Eds). Churchill Livingstone, Oxford, UK, 2701–2706 (2005).
   Google Scholar
• Mattoo S, Foreman-Wykert AK, Cotter PA, Miller JF. Mechanisms of Bordetella pathogenesis. Front. Biosci.6, E168–E186 (2001).
   Google Scholar
• Carbonetti NH. Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease. Curr. Opin. Pharmacol.7, 272–278 (2007).
   Google Scholar
• Greenberg DP, von Konig CH, Heininger U. Health burden of pertussis in infants and children. Pediatr. Infect. Dis. J.24, S39–S43 (2005).
   PubMedGoogle Scholar
• Rothstein E, Edwards K. Health burden of pertussis in adolescents and adults. Pediatr. Infect. Dis. J.24, S44–S47 (2005).
   PubMed Web of Science ®Google Scholar
• Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr. Infect. Dis. J.24, S25–S34 (2005).
   PubMedGoogle Scholar
• Hewlett EL, Edwards KM. Clinical practice. Pertussis – not just for kids. N. Engl. J. Med.352, 1215–1222 (2005).
   PubMed Web of Science ®Google Scholar
• Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr. Infect. Dis. J.24, S10–S18 (2005).
   PubMed Web of Science ®Google Scholar
• Bamberger ES, Srugo I. What is new in pertussis? Eur. J. Pediatr.167, 133–139 (2008).
   PubMedGoogle Scholar
• Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics115, 1422–1427 (2005).
   PubMed Web of Science ®Google Scholar
• Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA. Epidemiological features of pertussis in the United States, 1980–1989. Clin. Infect. Dis.14, 708–719 (1992).
   PubMed Web of Science ®Google Scholar
• Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics100, E10 (1997).
   PubMedGoogle Scholar
• Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr. Infect. Dis. J.22, 628–634 (2003).
   PubMed Web of Science ®Google Scholar
• Cherry JD. The science and fiction of the ‘resurgence’ of pertussis. Pediatrics112, 405–406 (2003).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, De Serres G, MacDonald D et al. The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis.185, 1448–1453 (2002).
   PubMed Web of Science ®Google Scholar
• Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin. Infect. Dis.32, 1691–1697 (2001).
   PubMed Web of Science ®Google Scholar
• Greenberg DP. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr. Infect. Dis. J.24, 721–728 (2005).
   PubMed Web of Science ®Google Scholar
• Brennan M, Strebel P, George H et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis studies. J. Infect. Dis.181, 210–215 (2000).
   PubMedGoogle Scholar
• Mink CA, Sirota NM, Nugent S. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch. Pediatr. Adolesc. Med.148, 153–157 (1994).
   PubMed Web of Science ®Google Scholar
• Moore DM, Mathias RG. Patterns of susceptibility in an outbreak of Bordetella pertussis: evidence from a community-based study. Can. J. Infect. Dis.13, 305–310 (2002).
   Google Scholar
• Takayama N, Watanabe H, Fujita I, Minamitani M. Seroepidemiology of pertussis in the Japanese population. Med. Microbiol. Immunol.178, 1–8 (1989).
   Google Scholar
• Cromer BA, Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA. Unrecognized pertussis infection in adolescents. Am. J. Dis. Child.147, 575–577 (1993).
   PubMedGoogle Scholar
• Deville JG, Cherry JD, Christenson PD et al. Frequency of unrecognized Bordetella pertussis infections in adults. Clin. Infect. Dis.21, 639–642 (1995).
   PubMed Web of Science ®Google Scholar
• Cattaneo LA, Reed GW, Haase DH, Wills MJ, Edwards KM. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. J. Infect. Dis.173, 1256–1259 (1996).
   PubMedGoogle Scholar
• Garcia-Corbeira P, Dal-Re R, Aguilar L, Garcia-de-Lomas J. Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study. Vaccine18, 2173–2176 (2000).
   PubMed Web of Science ®Google Scholar
• Chiu TF, Lee CY, Lee PI, Lu CY, Lin HC, Huang LM. Pertussis seroepidemiology in Taipei. J. Formos Med. Assoc.99, 224–228 (2000).
   Google Scholar
• Hodder SL, Cherry JD, Mortimer EA Jr, Ford AB, Gornbein J, Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin. Infect. Dis.31, 7–14 (2000).
   PubMed Web of Science ®Google Scholar
• Lin YC, Yao SM, Yan JJ et al. Epidemiological shift in the prevalence of pertussis in Taiwan: implications for pertussis vaccination. J. Med. Microbiol.56, 533–537 (2007).
   PubMed Web of Science ®Google Scholar
• Lin YC, Yao SM, Yan JJ et al. Molecular epidemiology of Bordetella pertussis in Taiwan, 1993–2004: suggests one possible explanation for the outbreak or pertussis in 1997. Microbes Infect.8, 2082–2087 (2006).
   PubMed Web of Science ®Google Scholar
• Weber C, Boursaux-Etude G, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol.39, 4396–4403 (2001).
   PubMed Web of Science ®Google Scholar
• Denöel P, Godfroid F, Guiso N, Hallander H, Poolman J. Comparison of acellular pertussis vaccine-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine23, 5333–5341 (2005).
   PubMed Web of Science ®Google Scholar
• Schellekens J, von Konig CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr. Infect. Dis. J.24, S19–S24 (2005).
   PubMedGoogle Scholar
• Crowcroft NS, Booy R, Harrison T et al. Severe and unrecognised: pertussis in UK infants. Arch. Dis. Child.88, 802–806 (2003).
   PubMed Web of Science ®Google Scholar
• Tan T. Summary: epidemiology of pertussis. Pediatr. Infect. Dis. J.24, S35–S38 (2005).
   Google Scholar
• Bland J, Clements J. Protecting the world’s children: the story of WHO’s immunization programme. World Health Forum19, 162–173 (1998).
   Google Scholar
• Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr. Infect. Dis. J.6, 1351–1356 (1987).
   Google Scholar
• Miller DL, Ross EM, Alderslade R, Bellman MH, Rawson NSB. Pertussis immunization and serious acute neurological illness in children. Br. Med. J.282, 1595–1599 (1981).
   PubMed Web of Science ®Google Scholar
• Barkin RM, Pichichero ME. Diphtheria–pertussis–tetanus vaccine: reactogenicity of commercial products. Pediatrics45, 4245–4252 (1979).
   Google Scholar
• Broder KR, Cortese MM, Iskander JK et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-3), 1–34 (2006).
   PubMedGoogle Scholar
• Nennig ME, Shinefield HR, Edwards KM et al. Prevalence and incidence of adult pertussis in an urban population. JAMA275, 1672–1674 (1996).
   PubMed Web of Science ®Google Scholar
• Bass JW, Wittler RR. Return of epidemic pertussis in the United States. Pediatr. Infect. Dis. J.13, 343–345 (1994).
   PubMed Web of Science ®Google Scholar
• Nelson JD. The changing epidemiology of pertussis in young infant: the role of adults as reservoirs of infection. Am. J. Dis. Child.132, 371–373 (1978).
   PubMedGoogle Scholar
• Cassone A, Ausiello CM, Urbani F et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Arch. Pediatr. Adolesc. Med.151(3), 283–289 (1997).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Green JL, Francis AB, Marsocci SM, Murphy AM, Buscarino C. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Scand. J. Infect. Dis.28(2), 159–163 (1996).
   PubMed Web of Science ®Google Scholar
• Salmaso S, Mastrantonio P, Tozzi AE et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics108(5), E81 (2001).
   PubMed Web of Science ®Google Scholar
• Tinnion O, Hanlon M. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst. Rev.16(2), CD001478 (2008).
   Google Scholar
• Theeten H, Van Damme P, Hoppenbrouwersb K et al. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine23(12), 1515–1521 (2005).
   PubMed Web of Science ®Google Scholar
• Zepp F, Cheuvart B, Wolter JM. Anti-diphtheria antibodies should persist until after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (DTPA) in pre-school-aged children. Presented at: 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Giardini Naxos, Taormina, Sicily, 9–11 April 2003 (Abstract 281.00 plus poster).
   Google Scholar
• Kowuson P, Warachit B, Hutagalung Y et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria–tetanus–acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine21, 4192–4200 (2003).
   Google Scholar
• Zepp F, Habermehl P, Knuf M, Mannhardt-Laakman W, Howe B, Friedland LR. Immunogenicity of reduced antigen content tetanus–diphtheria–acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine25(29), 5248–5252 (2007).
   PubMedGoogle Scholar
• Knuf M, Zepp F, Meyer C et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine24(12), 2043–2048 (2006).
   PubMedGoogle Scholar
• Chan SH, Tan PT, Han HH, Bock HL. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria–tetanus–acellular pertussis vaccine as a single-dose booster in Singaporean adults. Singapore Med. J.47(4), 286–290 (2006).
   Google Scholar
• Van Damme P, Burgess M. Immunogenicity of a combined diphtheria–tetanus–acellular pertussis vaccine in adults. Vaccine22(3–4), 305–308 (2004).
   PubMed Web of Science ®Google Scholar
• Huang LM, Chang LY, Tang H et al. Immunogenicity and reactogenicity of a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine in healthy Taiwanese children and adolescents. J. Adolesc. Health37(6), 517e1–517e5 (2005).
   Google Scholar
• Sänger R, Behre U, Krause KH et al. Booster vaccination and 1-year follow-up of 4–8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur. J. Pediatr.166(12), 1229–1236 (2007).
   PubMedGoogle Scholar
• Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children. Hum. Vaccin.4(3), 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• Abarca K, Valdivieso F, Potin M, Ibáñez I, Vial P. Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine (dTpa) in 10 to 11 years old children and in adults. Rev. Med. Chil.130(5), 502–510 (2002).
   Google Scholar
• Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics117(4), 1084–1093 (2006).
   PubMedGoogle Scholar
• Southern J, Andrews N, Burrage M, Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine23(29), 3829–3835 (2005).
   PubMed Web of Science ®Google Scholar
• Edelman K, He Q, Mäkinen J et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin. Infect. Dis.44(10), 1271–1277 (2007).
   PubMedGoogle Scholar
• Meyer CU, Zepp F, Decker M et al. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Clin. Vaccine Immunol.14(3), 288–292 (2007).
   Google Scholar
• Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of age. Vaccine27(5), 765–772 (2009).
   Google Scholar
• Ward JI, Cherry JD, Chang SJ et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med.353(15), 1555–1563 (2005).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Rennels MB, Edwards KM et al. Combined tetanus, diphtheria, and 5-compoment pertussis vaccine for use in adolescents and adults. JAMA293(24), 3003–3011 (2005).
   PubMed Web of Science ®Google Scholar
• McIntyre PB, Turnbull FM, Egan AM et al. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria–tetanus–acellular pertussis vaccine. Vaccine23(3), 380–385 (2004).
   PubMedGoogle Scholar
• Bailleuxa F, Coudeville L, Kolenc-Sabanb A, Bevilacquab J, Barretob L, Andre P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine26, 3903–3908 (2008).
   Google Scholar
• Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum. Vaccin.4(3), 30–36 (2007).
   Google Scholar
• Turnbull FM, Heath TC, Jalaludin BB, Burgess MA, Ramalho AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria–tetanus vaccine (Td) in adults. Vaccine19(6), 628–636 (2000).
   PubMed Web of Science ®Google Scholar
• Van der Wielen M, Van Damme P, Joossens E, François G, Meurice F, Ramalho A. A randomised controlled trial with a diphtheria–tetanus–acellular pertussis (dTpa) vaccine in adults. Vaccine18(20), 2075–2082 (2000).
   PubMed Web of Science ®Google Scholar
• Bose A, Dubey AP, Gandhi D et al. Safety and reactogenicity of a low dose diphtheria tetanus acellular pertussis vaccine (Boostrix) in pre-school Indian children. Indian Pediatr.44(6), 421–424 (2007).
   Google Scholar
• Tran Minh NN, He Q, Ramalho A et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics104(6), e70 (1999).
   Google Scholar
• Sandora TJ, Pfoh E, Lee GM. Adverse events after administration of tetanus-diphtheria–acellular pertussis vaccine to healthcare workers. Infect. Control. Hosp. Epidemiol.30(4), 389–391 (2009).
   PubMedGoogle Scholar
• Van Der Wielen M, Van Damme P, Joossens E, Francois G, Meurice F, Ramalho A. A randomized controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine18(20), 2075–2082 (2000).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR, Francis AB et al. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Clin. Pediatr. (Phila.)45(7), 613–620 (2006).
   Google Scholar
• Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics115(6), 1675–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Lee GM, Riffelmann M, Wirsing von Konig CH. Cost–effectiveness of adult pertussis vaccination in Germany. Vaccine26(29–30), 3673–3679 (2008).
   PubMed Web of Science ®Google Scholar
• Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am. J. Prev. Med.32(3), 186–193 (2007).
   PubMed Web of Science ®Google Scholar
• Hay JW, Ward JI. Economic considerations for pertussis booster vaccination in adolescents. Pediatr. Infect. Dis. J.24(6 Suppl.), S127–S133 (2005).
   Google Scholar
• Iskedjian M, Walker JH, De Serres G, Einarson TR. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. Paediatr. Drugs7(2), 123–136 (2005).
   PubMedGoogle Scholar
• Franco E, Giambi C, Ialacci R, Maurici M. Pertussis vaccination for adolescents and adults. Expert Opin. Biol. Ther.4(10), 1669–1676 (2004).
   PubMed Web of Science ®Google Scholar
• Jeffrey PD. Clinical and economic effects of pertussis outbreaks. Pediatr. Infect. Dis. J.24, S109–S116 (2005).
   Google Scholar
• Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine22(23–24), 3154–3165 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy TV, Slade BA, Broder KR et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.57(RR-4), 1–51 (2008).
   PubMedGoogle Scholar
• Halperin S, Sweet L, Baxendale D. How soon after a prior tetanus–diphtheria vaccination can one give adult formulation tetanus–diphtheria–acellular pertussis vaccine? Pediatr. Infect. Dis. J.25, 195–200 (2006).
   PubMed Web of Science ®Google Scholar
• Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the advisory committee on immunization practices (ACIP) and recommendation of ACIP, supported by the healthcare infection control practices advisory committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm. Rep.55(RR-17), 1–33 (2006).
   PubMedGoogle Scholar